SCHEMBL29831714

SCHEMBL29831714

CSc1nc2ccc(Br)cc2c(=O)n1-c1ccc(F)c(F)c1F

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 6/20 1.00
PDE4A P27815 2/20 0.46
PDE4B Q07343 2/20 0.46
PDE4C Q08493 2/20 0.46
PDE4D Q08499 2/20 0.46
PDE7B Q9NP56 2/20 0.46
SLC22A12 Q96S37 1/20 0.41
ATM Q13315 2/20 0.40
MAPT P10636 2/20 0.40
LMNA P02545 3/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PTGS2 P35354 1/20 0.39
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
IDO1 P14902 2/20 0.38
TDO2 P48775 2/20 0.38
IDO2 Q6ZQW0 2/20 0.38
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL291537 1.00 PDE7A (1.00) PDE7APDE4APDE4BPDE4CPDE4D
SCHEMBL290341 0.81 PDE7A (0.71) PDE7APDE4APDE4BPDE4CPDE4D
SCHEMBL29832076 0.80 PDE7A (0.66) PDE7APDE4APDE4BPDE4CPDE4D
SCHEMBL290297 0.80 PDE7A (0.66) PDE7APDE4APDE4BPDE4CPDE4D
SCHEMBL3337074 0.78 PDE7A (0.63) PDE7APDE4APDE4BPDE4CPDE4D
SCHEMBL4207211 0.74 PDE7A (0.58) PDE7AATMLMNAHPGDPTGS2
SCHEMBL9954930 0.73 POLB (0.58) PDE7APDE4APDE4BPDE4CPDE4D
SCHEMBL29831678 0.73 PDE7A (0.70) PDE7APDE4APDE4BPDE4CPDE4D
SCHEMBL291706 0.73 PDE7A (0.70) PDE7APDE4APDE4BPDE4CPDE4D
SCHEMBL13325532 0.73 PDE7A (0.57) PDE7APDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4572765-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE Mitodicure GmbH (DE) 2025-06-25 EP disclosed
WO-2024038089-A1 USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE MITODICURE GMBH (DE) 2024-02-22 WO disclosed
EP-4275752-A2 TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS Omeros Corporation (US) 2023-11-15 EP disclosed
CN-115192711-A Use of PDE7 inhibitors for the treatment of movement disorders 奥默罗斯公司 2022-10-18 CN disclosed
CN-114984229-A Treatment of addiction and impulse control disorders using PDE7 inhibitors 奥默罗斯公司 2022-09-02 CN disclosed